182 related articles for article (PubMed ID: 24464805)
1. The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain.
Sane R; Wu SP; Zhang R; Gallo JM
Drug Metab Dispos; 2014 Apr; 42(4):537-40. PubMed ID: 24464805
[TBL] [Abstract][Full Text] [Related]
2. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo.
Vlaming ML; van Esch A; Pala Z; Wagenaar E; van de Wetering K; van Tellingen O; Schinkel AH
Mol Cancer Ther; 2009 Dec; 8(12):3350-9. PubMed ID: 19996279
[TBL] [Abstract][Full Text] [Related]
3. Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate.
Vlaming ML; van Esch A; van de Steeg E; Pala Z; Wagenaar E; van Tellingen O; Schinkel AH
Drug Metab Dispos; 2011 Aug; 39(8):1338-44. PubMed ID: 21566011
[TBL] [Abstract][Full Text] [Related]
4. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
Lin F; Marchetti S; Pluim D; Iusuf D; Mazzanti R; Schellens JH; Beijnen JH; van Tellingen O
Clin Cancer Res; 2013 Apr; 19(8):2084-95. PubMed ID: 23461902
[TBL] [Abstract][Full Text] [Related]
5. Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.
Vlaming ML; Pala Z; van Esch A; Wagenaar E; de Waart DR; van de Wetering K; van der Kruijssen CM; Oude Elferink RP; van Tellingen O; Schinkel AH
Clin Cancer Res; 2009 May; 15(9):3084-93. PubMed ID: 19383815
[TBL] [Abstract][Full Text] [Related]
6. Overlapping functions of ABC transporters in topotecan disposition as determined in gene knockout mouse models.
Tiwari AK; Zhang R; Gallo JM
Mol Cancer Ther; 2013 Jul; 12(7):1343-55. PubMed ID: 23635651
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models.
Wang Z; Zhou Q; Kruh GD; Gallo JM
Drug Metab Dispos; 2011 Nov; 39(11):2155-61. PubMed ID: 21841039
[TBL] [Abstract][Full Text] [Related]
8. Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
Li L; Agarwal S; Elmquist WF
Drug Metab Dispos; 2013 Mar; 41(3):659-67. PubMed ID: 23297298
[TBL] [Abstract][Full Text] [Related]
9. High-dose methotrexate in Egyptian pediatric acute lymphoblastic leukemia: the impact of ABCG2 C421A genetic polymorphism on plasma levels, what is next?
El Mesallamy HO; Rashed WM; Hamdy NM; Hamdy N
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1359-65. PubMed ID: 24718721
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
[TBL] [Abstract][Full Text] [Related]
11. Effects of putative catalytic base mutation E211Q on ABCG2-mediated methotrexate transport.
Hou YX; Li CZ; Palaniyandi K; Magtibay PM; Homolya L; Sarkadi B; Chang XB
Biochemistry; 2009 Sep; 48(38):9122-31. PubMed ID: 19691360
[TBL] [Abstract][Full Text] [Related]
12. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse.
Giri N; Shaik N; Pan G; Terasaki T; Mukai C; Kitagaki S; Miyakoshi N; Elmquist WF
Drug Metab Dispos; 2008 Aug; 36(8):1476-84. PubMed ID: 18443033
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one).
Mizuno N; Takahashi T; Kusuhara H; Schuetz JD; Niwa T; Sugiyama Y
Drug Metab Dispos; 2007 Nov; 35(11):2045-52. PubMed ID: 17682070
[TBL] [Abstract][Full Text] [Related]
15. cGMP transport by vesicles from human and mouse erythrocytes.
de Wolf CJ; Yamaguchi H; van der Heijden I; Wielinga PR; Hundscheid SL; Ono N; Scheffer GL; de Haas M; Schuetz JD; Wijnholds J; Borst P
FEBS J; 2007 Jan; 274(2):439-50. PubMed ID: 17229149
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.
Hill CR; Jamieson D; Thomas HD; Brown CD; Boddy AV; Veal GJ
Biochem Pharmacol; 2013 Jan; 85(1):29-37. PubMed ID: 23063411
[TBL] [Abstract][Full Text] [Related]
17. Influence of C6 and CNS1 brain tumors on methotrexate pharmacokinetics in plasma and brain tissue.
Dukic SF; Kaltenbach ML; Heurtaux T; Hoizey G; Lallemand A; Vistelle R
J Neurooncol; 2004; 67(1-2):131-8. PubMed ID: 15072460
[TBL] [Abstract][Full Text] [Related]
18. In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats.
Devineni D; Klein-Szanto A; Gallo JM
Cancer Chemother Pharmacol; 1996; 38(6):499-507. PubMed ID: 8823490
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse.
Zaher H; Khan AA; Palandra J; Brayman TG; Yu L; Ware JA
Mol Pharm; 2006; 3(1):55-61. PubMed ID: 16686369
[TBL] [Abstract][Full Text] [Related]
20. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
Cisternino S; Mercier C; Bourasset F; Roux F; Scherrmann JM
Cancer Res; 2004 May; 64(9):3296-301. PubMed ID: 15126373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]